Search company, investor...
Search
Marengo Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

marengotx.com

Stage

Corporate Minority | Alive

Total Raised

$164M

Last Raised

$45M | 2 mos ago

About Marengo Therapeutics

Marengo Therapeutics, an ATP company, is developing the next generation of T cell immune engagers that activate and expand a novel population of “superkiller” T cells. Marengo antibodies induce potent and durable anti-tumor responses in refractory solid tumor models and promote protective tumor immunity (“immune memory”) while triggering less pro-inflammatory cytokine release than anti-CD3 T cell engagers. Marengo’s lead project, a first- and -best-in-class therapy with single agent potential, is progressing to IND for PD1-refractory solid tumors. The company’s advanced antibody discovery platform has also generated a pipeline of multi-specific antibody therapies with potential in multiple tumor types. The company is based in Cambridge, Massachusetts.

Marengo Therapeutics Headquarters Location

Riverside Technology Center 840 Memorial Drive 4th Floor

Cambridge, Massachusetts, 02139,

United States

617-917-4980

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Marengo Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Marengo Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Marengo Therapeutics Patents

Marengo Therapeutics has filed 16 patents.

The 3 most popular patent topics include:

  • Immunology
  • Immune system
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/21/2017

4/5/2022

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Oncology

Grant

Application Date

3/21/2017

Grant Date

4/5/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Oncology

Status

Grant

Latest Marengo Therapeutics News

07:00 EDT Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors a...

Sep 16, 2022

News provided by Share this article Share this article CAMBRIDGE, Mass., Sept. 16, 2022 /PRNewswire/ -- Marengo Therapeutics, a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the right T cell subsets to fight cancer, today announced it is advancing its lead TCR activator, STAR0602, into the clinic following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). STAR0602 is a bi-functional fusion antibody that deploys a novel mechanism of T cell activation that has demonstrated potent single agent activity in PD-1 refractory settings in preclinical studies. Marengo plans to initiate a Phase I/II clinical trial of STAR0602 as a single agent in advanced solid tumors in the fourth quarter of 2022. To conduct the clinical trial for STAR0602 and advance translational research via the company's TCR Vβ targeted STAR platform, Marengo has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI)'s Center for Cancer Research (CCR) and its recently announced Center for Immuno-Oncology (CIO). The CIO is co-led by Dr. Jeffrey Schlom, Co-Director of CIO, and Dr. James Gulley, Co-Director of CIO, Deputy Director of the CCR, NCI, and acting Clinical Director, NCI. The NCI and its collaborators at Marengo Therapeutics, Inc. will conduct preclinical and clinical investigations of Marengo Therapeutics' selective immune activation antibody repertoire in cancer and other T cell-related diseases. This is the first CRADA with the newly formed CIO team at the NCI, which is one of the Institutes of the National Institutes of Health (NIH). "Advancing our lead asset into the clinic marks a key inflection point for Marengo as we begin to translate our novel discovery into life-saving medicines. The collaboration with NCI will help us accelerate enrollment for our clinical trial while ensuring that it is executed in accordance with the highest standards of ethics and quality," said Zhen Su, M.D., MBA, Chief Executive Officer of Marengo. "We are truly honored to be the CIO's first CRADA partner and look forward to combining our expertise with that of Dr. Gulley, Dr. Schlom, and their teams to create paradigm-shifting immunotherapeutics for patients. The studies conducted as part of this CRADA will help us expand the opportunities for our lead asset and the STAR platform to address high unmet medical needs." About Marengo Therapeutics Marengo Therapeutics, Inc, an ATP company, is pioneering first-in-class therapeutics that activate the right immune response to promote lifelong protection against cancer. With a passionate team of dedicated scientists experienced in immunology and oncology, Marengo's proprietary Selective T Cell Activation Repertoire (STAR) platform leverages an extensive biological understanding of T cell function and receptor signaling to create a world in which everyone's immune system can defeat cancer. To learn more, visit marengotx.com . About STAR0602 Marengo's STAR0602 program is the company's lead program and is the first T cell activator generated by the STAR platform. Marengo's Selective T Cell Activation Repertoire (STAR) platform is a multi-specific fusion protein library that targets specific TCR Vβ variants fused to different co-stimulatory moieties to develop potent T cell activators. The unique feature of this platform is to fine-tune the T cell response in selected T cell subsets to generate endogenous, highly functional, cancer-killing T cells for solid tumors. STAR0602, is a fusion protein that binds to a specific region of TCR Vβ and delivers a unique activation signal on the same T cell, leading to a selective expansion of the targeted T cell subclones. This molecule has shown remarkable single agent activity in a vast array of preclinical models. SOURCE Marengo Therapeutics

Marengo Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Marengo Therapeutics Rank

  • Where is Marengo Therapeutics's headquarters?

    Marengo Therapeutics's headquarters is located at Riverside Technology Center, Cambridge.

  • What is Marengo Therapeutics's latest funding round?

    Marengo Therapeutics's latest funding round is Corporate Minority.

  • How much did Marengo Therapeutics raise?

    Marengo Therapeutics raised a total of $164M.

  • Who are the investors of Marengo Therapeutics?

    Investors of Marengo Therapeutics include Ipsen Group and Apple Tree Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.